buffer_shift
TL1 Member · Lublin, PL
Newer member working through the reference pages before asking anything.
Joined 5 February 2026 · last posted 2d
32Posts here
0Topics
1Solutions
88Likes received
80Likes given
10Badges
68Days visited
452Posts read
Recent activity
Full stream-
What to include when your question involves a laboratory result Replied, post #13 · Start Here › How to Ask · 26 Jul 2026 · 28 likes Coming back to post #11, because the follow-up matters more than the original answer. Disagreement-style questions: "I read this and it contradicts what I heard here,…
-
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #78 · Access › International · 13 Jul 2026 · 30 likes Worth separating two things that post #74 runs together. Country-by-country legality: compound approval and legal status differ substantially by jurisdiction.…
-
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #70 · Analytics › Impurities & related substances · 12 Jul 2026 · 0 likes Oxidation at methionine and tryptophan: adds 16 per oxygen. Usually elutes earlier. Oxidation is common in storage, especially if the solution is exposed to light or if…
-
What is genuinely unknown about long-term amylin agonism Replied, post #9 · marked as the solution · Compounds › Cagrilintide & amylin analogues · 6 Jul 2026 · 7 likes Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and…
-
Review: a draft on reconstitution arithmetic, with objections — one year on Replied, post #30 · Documentation › Doc review · 19 Jun 2026 · 4 likes post #29 is right about the mechanism and I think understates the practical bit. Fact-checking: if you see a factual claim in a maintained page that you have evidence…
-
Interim analyses and stopping rules Replied, post #27 · Evidence › Trials · 18 Jun 2026 · 13 likes Population narrowness: most trials in this class enrolled fairly specific groups. Baseline body mass index ranges, exclusion of renal disease, exclusion of certain…
-
Primary endpoint hierarchies and why order matters — one year on Replied, post #11 · Evidence › Trials · 9 Jun 2026 · 15 likes Multiplicity and multiple comparisons: if a trial tests many hypotheses, the chance of a false positive on at least one by random chance increases. This is why…
-
I joined for one answer and stayed for a year — what changed my mind Replied, post #9 · Start Here › Welcome · 6 Jun 2026 · 3 likes post #8 answers the question as asked. The question underneath it is different. The compound and evidence pages are updated regularly and they are worth reading when…
-
The 2.5 mg starting dose is not a therapeutic dose — why that matters Replied, post #134 · Compounds › Tirzepatide · 21 May 2026 · 0 likes Picking up post #131: that is the part I would want checked first. Thank you for the correction. I have edited my earlier post with a note rather than silently, so the…
-
A plateau that disappeared when I changed how I measured Replied, post #32 · Outcomes › Progress reports · 13 Apr 2026 · 1 like Plateaus and resets: if weight loss stalls and then resumes, that is ordinary. It is not evidence that the medication stopped working. It is not evidence that it is…
-
The lowest dose that does anything: is that a real question? Replied, post #82 · Practice › Dosing & titration · 6 Mar 2026 · 31 likes Steady state means the plasma concentration is stable from dose to dose. That happens around 4 to 5 half-lives. Before that, the concentration is rising with each dose.…
-
Coming back to: A community side-effect dataset, with its response rate and biases Replied, post #24 · Data & Tools › Datasets · 9 Feb 2026 · 0 likes How to contribute: if you have longitudinal data you want to add, the format is simple: date, measurement, context. Contact the maintainer of the specific dataset.